MedPath

Fruquintinib

Generic Name
Fruquintinib
Brand Names
Fruzaqla
Drug Type
Small Molecule
Chemical Formula
C21H19N3O5
CAS Number
1194506-26-7
Unique Ingredient Identifier
49DXG3M5ZW
Background

Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication

本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Clinical Trials
Related News

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer

Phase 1
Active, not recruiting
Conditions
Triple Negative Breast Cancer
HER2-negative Breast Cancer
Advanced Solid Tumors
Metastatic Colon Cancer
Metastatic Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Rectal Cancer
Interventions
First Posted Date
2017-08-16
Last Posted Date
2023-02-10
Lead Sponsor
Hutchmed
Target Recruit Count
129
Registration Number
NCT03251378
Locations
🇺🇸

St. Joseph Heritage Healthcare, Santa Rosa, California, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 6 locations

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
NSCLC
Interventions
First Posted Date
2016-11-29
Last Posted Date
2019-11-15
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
50
Registration Number
NCT02976116
Locations
🇨🇳

The First Hospital of Zhejiang University, Hangzhou, China

🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 3
Completed
Conditions
NSCLC
Interventions
Drug: Placebo
First Posted Date
2016-02-25
Last Posted Date
2019-02-12
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
527
Registration Number
NCT02691299
Locations
🇨🇳

The First Affiliated Hosptial of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

🇨🇳

The First Hospital of Jilin University, Changchun, Jilin, China

🇨🇳

307 Hospital of PLA, Beijing, Beijing, China

and more 8 locations

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-02-24
Last Posted Date
2020-02-13
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
6
Registration Number
NCT02689752
Locations
🇨🇳

Jiangsu Province Hospital, Nanjing, Jiangsu, China

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Placebo
First Posted Date
2015-10-29
Last Posted Date
2020-02-13
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
91
Registration Number
NCT02590965
Locations
🇨🇳

307 Hospital of PLA, Beijing, Beijing, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Xi Nan Hospital, Third Military Medical University, Chongqing, Chongqing, China

and more 9 locations

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

Phase 3
Completed
Conditions
Colorectal Cancer
Interventions
Drug: placebo
First Posted Date
2014-12-11
Last Posted Date
2020-02-17
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
416
Registration Number
NCT02314819
Locations
🇨🇳

Hutchison Medi Pharma Investigational Site, Hangzhou, Zhejiang, China

🇨🇳

Hutchison Medi Pharma investigational site, Shenzhen, Guangdong, China

🇨🇳

Hutchison Medi pharma Investigational Site, Beijing, Beijing, China

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Drug: placebo
First Posted Date
2014-07-22
Last Posted Date
2020-06-16
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
71
Registration Number
NCT02196688
Locations
🇨🇳

Hutchison Medi Pharma Investigational Site, Shanghai, China

🇨🇳

Hutchison Medi Pharma, Harbin, Heilongjiang, China

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Phase 1
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2013-11-03
Last Posted Date
2020-02-17
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
62
Registration Number
NCT01975077
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

Fudan University Cancer Center, Shanghai, Shanghai, China

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Phase 1
Completed
Conditions
Food Effect of Fruquintinib in Health Subjects
Interventions
First Posted Date
2013-10-07
Last Posted Date
2020-02-17
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
20
Registration Number
NCT01955304
Locations
🇨🇳

Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Tumor
Interventions
First Posted Date
2012-07-20
Last Posted Date
2020-02-17
Lead Sponsor
Hutchison Medipharma Limited
Target Recruit Count
40
Registration Number
NCT01645215
Locations
🇨🇳

Fudan University Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy